Description

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

The Cancer Research UK Cancer Therapeutics Unit, within the Division of Cancer Therapeutics, is a multidisciplinary ‘bench to bedside’ centre, dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Division’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial This Unit is now under the leadership of Professor Rajesh Chopra who has previously held senior leadership positions at AstraZeneca and Celgene for postdoc and academic positions in the UK in haematological oncology and stem cell transplantation.

We are seeking a highly motivated Biologist to work in our new Translational Cancer Discovery Team (led by Professor Rajesh Chopra), located in well-equipped laboratories in Sutton, South London. The successful applicant will undertake a focused project using a small molecule library to screen for cancer drugs that targets pancreatic ductal adenocarcinoma, stellate cancer associated fibroblasts, and surrounding immune cells.

The Translational Cancer Discovery Team use molecular, biochemical and cellular techniques to validate the molecular target and identify biomarkers of compounds that target a variety of difficult to drug targets such as c-myc and WNT signalling. In addition we are developing novel organotypic assays of cancer cells in order to undertake cancer drug screening in a physiologically relevant context. Finally the team will deploy novel approaches to modulate antigen presentation, for tumour elimination or prevention of escape.

The successful candidate will conduct plate-based assays according to existing protocols to measure effects on proliferation, survival and signalling.

oAppropriately analyse data and post to internal databases

oReport findings

Candidates should possess a PhD in Biochemistry, Molecular Biology or Cell Biology, have developed a range of skills through experience in these areas and be able to work in an interdisciplinary environment towards the goal of performing cellular immunological and biochemical assays required drug development. Knowledge of cancer research and for immunology and familiarity with contemporary approaches to drug discovery, molecular target validation is desirable. Starting salary in the region of £29,660 – £40,530 pa inclusive (based on previous experience.

Leave a reply

Medgenera is a New York and New Delhi-based healthcare news publication company actively supported by 120,000 monthly readers and subscribers in 43 countries, including the healthcare professionals at the 14 out of 25 biggest pharmaceutical companies.